Travere Therapeutics Presents New Biomarker Data for FILSPARI at ASN Kidney Week 2026

At the ASN Kidney Week 2026, Travere Therapeutics presented new biomarker data from its Phase 3 PROTECT study, indicating that FILSPARI (sparsentan) may alter the disease pathophysiology in patients with IgA nephropathy. The findings provide additional insights into the medication's dual mechanism of action, underscoring the company's commitment to showcasing the clinical benefits of its lead product for rare kidney diseases.